Characteristics of patients diagnosed with both melanoma and renal cell cancer

[1]  S. Batra,et al.  Incidence and Prognostic Significance of Second Primary Cancers in Renal Cell Carcinoma , 2013, American journal of clinical oncology.

[2]  C. Wood,et al.  Environmental and modifiable risk factors in renal cell carcinoma. , 2012, Urologic oncology.

[3]  Barbara Sennino,et al.  Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. , 2012, Cancer discovery.

[4]  B. Henderson,et al.  Risk Factors for Malignant Melanoma in White and Non-White/Non–African American Populations: The Multiethnic Cohort , 2012, Cancer Prevention Research.

[5]  S. Puig,et al.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.

[6]  J. Patard,et al.  Characteristics of the coexistence of melanoma and renal cell carcinoma , 2010, Cancer.

[7]  B. Kavanagh,et al.  Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control , 2010, Radiation oncology.

[8]  M. Abdel-Rahman,et al.  MET oncogene inhibition as a potential target of therapy for uveal melanomas. , 2010, Investigative ophthalmology & visual science.

[9]  M. Tucker,et al.  Increased risk of second primary cancers after a diagnosis of melanoma. , 2010, Archives of dermatology.

[10]  F. Marincola,et al.  Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Paci,et al.  The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries) , 2008, Melanoma research.

[12]  R. Supramaniam.  New malignancies among cancer survivors: SEER cancer registries, 1973–2000 , 2008, Journal of Epidemiology & Community Health.

[13]  R. Salgia,et al.  c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma , 2007, Clinical Cancer Research.

[14]  Yu-Hung Wu,et al.  The association between malignant melanoma and noncutaneous malignancies , 2006, International journal of dermatology.

[15]  C. Beisland,et al.  Multiple primary malignancies in patients with renal cell carcinoma: a national population‐based cohort study , 2006, BJU international.

[16]  S. Kim-Schulze,et al.  Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  David Sidransky,et al.  Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. , 2003, Cancer research.

[18]  G. Plewig,et al.  Risk of second primary malignancies in patients with cutaneous melanoma , 2001, The British journal of dermatology.

[19]  P. Choyke,et al.  Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. , 1999, The American journal of pathology.

[20]  A. Eggermont,et al.  Redefining the role of interferon in the treatment of malignant diseases. , 2010, European journal of cancer.

[21]  R. Hoover,et al.  New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. , 2006 .

[22]  A. Weaver,et al.  Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. , 2001, Genetic testing.

[23]  Hardeo Sahai,et al.  Confidence Intervals for the Mean of a Poisson Distribution: A Review , 1993 .

[24]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .